advertisement
Abstract #27873 Published in IGR 13-1
Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75(NTR) activity is neurotoxic through a paracrine mechanism
Bai Y; Dergham P; Nedev H; Xu J; Galan A; Rivera JC; ZhiHua S; Mehta HM; Woo SB; Sarunic MVJournal of Biological Chemistry 2010; 285: 39392-39400
In normal adult retinas, NGF receptor TrkA is expressed in retinal ganglion cells (RGC), whereas glia express p75(NTR). During retinal injury, endogenous NGF, TrkA, and p75(NTR) are up-regulated. Paradoxically, neither endogenous NGF nor exogenous administration of wild type NGF can protect degenerating RGCs, even when administered at high frequency. Here we elucidate the relative contribution of NGF and each of its receptors to RGC degeneration in vivo. During retinal degeneration due to glaucoma or optic nerve transection, treatment with a mutant NGF that only activates TrkA, or with a biological response modifier that prevents endogenous NGF and pro-NGF from binding to p75(NTR) affords significant neuroprotection. Treatment of normal eyes with an NGF mutant-selective p75(NTR) agonist causes progressive RGC death, and in injured eyes it accelerates RGC death. The mechanism of p75 (NTR) action during retinal degeneration due to glaucoma is paracrine, by increasing production of neurotoxic proteins TNF-(alpha) and (alpha)(2)-macroglobulin. Antagonists of p75(NTR) inhibit TNF-(alpha) and (alpha)(2)-macroglobulin up-regulation during disease, and afford neuroprotection. These data reveal a balance of neuroprotective and neurotoxic mechanisms in normal and diseased retinas, and validate each neurotrophin receptor as a pharmacological target for neuroprotection.
H. U. Saragovi. Lady Davis Institute-Jewish General Hospital, Montreal, QC H3T 1E2, Canada. uri.saragovi@mcgill.ca
Classification:
11.8 Neuroprotection (Part of: 11 Medical treatment)
5.1 Rodent (Part of: 5 Experimental glaucoma; animal models)
